Recently, Ribas and colleagues extensively studied this aspect and proved several times that the exceptional response to anti PD-1 (75% ORR) of melanoma patients was severely compromised due to defects in the pathway involved in interferon-receptor signaling [208]. The gene discussed is PDCD1; the disease is melanoma.